Compass Therapeutics (CMPX) Change in Accured Expenses (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Change in Accured Expenses data on file, last reported at -$3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 148.84% year-over-year to -$3.4 million; the trailing twelve-month figure through Mar 2026 stood at -$5.2 million (down 145.74% YoY), and the FY2025 full-year result was $5.1 million, up 35.06% from the prior year.
• Change in Accured Expenses retreated to -$3.4 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $6.9 million in Q1 2025 to a low of -$5.4 million in Q2 2022.
• A 5-year average of -$45588.2 and a median of -$1.1 million in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses plunged 12354.55% in 2022 and jumped 1090.99% in 2025, its largest moves.
• Tracing CMPX's Change in Accured Expenses over 5 years: stood at $5.9 million in 2022, then tumbled by 152.62% to -$3.1 million in 2023, then soared by 207.7% to $3.4 million in 2024, then fell by 19.93% to $2.7 million in 2025, then sank by 225.34% to -$3.4 million in 2026.
• Business Quant data shows CMPX's Change in Accured Expenses at -$3.4 million in Q1 2026, $2.7 million in Q4 2025, and -$2.3 million in Q3 2025.